Home | Structured Search | Drug Resource
Find: within
Dengue > Drug Therapy Author: Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath; Panduka Karunanayake, MD, MRCP; Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP
Editorial changes - 2009-11-13
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • There is no specific antiviral drug therapy for dengue.
  • Different drugs can be used to manage symptoms and treat complications.

Evidence:

  • A randomized, controlled study compared treatment with intravenous immunoglobulin (n = 15) vs. no treatment (n = 16) to determine whether a high dose of intravenous immunoglobulin is effective in hastening recovery from thrombocytopenia in patients with secondary dengue virus infection. No significant difference was found in the baseline demographic data between the two groups. No adverse effect of intravenous immunoglobulin was observed, but no effect in hastening the recovery of platelet counts was found in patients with secondary dengue virus infection (108).

Comments:

  • Drugs are only useful in patients with dengue to manage symptoms and treat complications, such as liver failure, heart failure, and superadded infections.

FAQs
Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Panduka Karunanayake, MD, MRCP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.